Long‐term outcome following imatinib therapy for chronic myelogenous leukemia, with assessment of dosage and blood levels: the JALSG CML202 study (Q54527295)

From Wikidata

Jump to navigation Jump to search

scientific article published on April 16, 2012

Language	Label	Description	Also known as
English	Long‐term outcome following imatinib therapy for chronic myelogenous leukemia, with assessment of dosage and blood levels: the JALSG CML202 study	scientific article published on April 16, 2012

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

30 May 2018

http://europepmc.org/abstract/MED/22364419

Long‐term outcome following imatinib therapy for chronic myelogenous leukemia, with assessment of dosage and blood levels: the JALSG CML202 study (English)

reason for preferred rank

most precise value

1 reference

10.1111/J.1349-7006.2012.02253.X

https://api.crossref.org/works/10.1111/J.1349-7006.2012.02253.X

25 December 2024

Long-term outcome following imatinib therapy for chronic myelogenous leukemia, with assessment of dosage and blood levels: the JALSG CML202 study (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC:MED AND EXT_ID:22364419

25 December 2024

1 reference

based on heuristic

inferred from title

Chiaki Nakaseko

2

object named as

Chiaki Nakaseko

1 reference

Europe PubMed Central

PubMed publication ID

30 May 2018

http://europepmc.org/abstract/MED/22364419

12

object named as

Noriko Usui

1 reference

Europe PubMed Central

PubMed publication ID

30 May 2018

http://europepmc.org/abstract/MED/22364419

author name string

Kazunori Ohnishi

1

1 reference

Europe PubMed Central

PubMed publication ID

30 May 2018

http://europepmc.org/abstract/MED/22364419

Jin Takeuchi

3

1 reference

Europe PubMed Central

PubMed publication ID

30 May 2018

http://europepmc.org/abstract/MED/22364419

Shin Fujisawa

4

1 reference

Europe PubMed Central

PubMed publication ID

30 May 2018

http://europepmc.org/abstract/MED/22364419

Tadashi Nagai

5

1 reference

Europe PubMed Central

PubMed publication ID

30 May 2018

http://europepmc.org/abstract/MED/22364419

Hirohito Yamazaki

6

1 reference

Europe PubMed Central

PubMed publication ID

30 May 2018

http://europepmc.org/abstract/MED/22364419

Tetsuzo Tauchi

7

1 reference

Europe PubMed Central

PubMed publication ID

30 May 2018

http://europepmc.org/abstract/MED/22364419

Kiyotoshi Imai

8

1 reference

Europe PubMed Central

PubMed publication ID

30 May 2018

http://europepmc.org/abstract/MED/22364419

Naoki Mori

9

1 reference

Europe PubMed Central

PubMed publication ID

30 May 2018

http://europepmc.org/abstract/MED/22364419

Fumiharu Yagasaki

10

1 reference

Europe PubMed Central

PubMed publication ID

30 May 2018

http://europepmc.org/abstract/MED/22364419

Yasuhiro Maeda

11

1 reference

Europe PubMed Central

PubMed publication ID

30 May 2018

http://europepmc.org/abstract/MED/22364419

Yasushi Miyazaki

13

1 reference

Europe PubMed Central

PubMed publication ID

30 May 2018

http://europepmc.org/abstract/MED/22364419

Koichi Miyamura

14

1 reference

Europe PubMed Central

PubMed publication ID

30 May 2018

http://europepmc.org/abstract/MED/22364419

Hitoshi Kiyoi

15

1 reference

Europe PubMed Central

PubMed publication ID

30 May 2018

http://europepmc.org/abstract/MED/22364419

Shigeki Ohtake

16

1 reference

Europe PubMed Central

PubMed publication ID

30 May 2018

http://europepmc.org/abstract/MED/22364419

Tomoki Naoe

17

1 reference

Europe PubMed Central

PubMed publication ID

30 May 2018

http://europepmc.org/abstract/MED/22364419

Japan Adult Leukemia Study Group

18

1 reference

Europe PubMed Central

PubMed publication ID

30 May 2018

http://europepmc.org/abstract/MED/22364419

language of work or name

1 reference

National Center for Biotechnology Information

PubMed publication ID

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=22364419

25 December 2024

publication date

16 April 2012

1 reference

Europe PubMed Central

PubMed publication ID

30 May 2018

http://europepmc.org/abstract/MED/22364419

full work available at URL

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7685081

HyperText Markup Language

online access status

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC:MED AND EXT_ID:22364419

25 December 2024

https://europepmc.org/articles/PMC7685081

HyperText Markup Language

online access status

content deliverer

Europe PubMed Central

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC:MED AND EXT_ID:22364419

25 December 2024

https://europepmc.org/articles/PMC7685081?pdf=render

online access status

content deliverer

Europe PubMed Central

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC:MED AND EXT_ID:22364419

25 December 2024

https://doi.org/10.1111/j.1349-7006.2012.02253.x

online access status

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC:MED AND EXT_ID:22364419

25 December 2024

https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1111/j.1349-7006.2012.02253.x

1 reference

10.1111/J.1349-7006.2012.02253.X

https://api.crossref.org/works/10.1111/J.1349-7006.2012.02253.X

25 December 2024

https://onlinelibrary.wiley.com/doi/pdf/10.1111/j.1349-7006.2012.02253.x

1 reference

10.1111/J.1349-7006.2012.02253.X

https://api.crossref.org/works/10.1111/J.1349-7006.2012.02253.X

25 December 2024

1 reference

Europe PubMed Central

PubMed publication ID

30 May 2018

http://europepmc.org/abstract/MED/22364419

103

1 reference

Europe PubMed Central

PubMed publication ID

30 May 2018

http://europepmc.org/abstract/MED/22364419

6

1 reference

Europe PubMed Central

PubMed publication ID

30 May 2018

http://europepmc.org/abstract/MED/22364419

1071-1078

1 reference

Europe PubMed Central

PubMed publication ID

30 May 2018

http://europepmc.org/abstract/MED/22364419

Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1111/J.1349-7006.2012.02253.X

21 January 2018

Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet

1 reference

https://api.crossref.org/works/10.1111/J.1349-7006.2012.02253.X

21 January 2018

Imatinib for newly diagnosed patients with chronic myeloid leukemia: incidence of sustained responses in an intention-to-treat analysis

1 reference

https://api.crossref.org/works/10.1111/J.1349-7006.2012.02253.X

21 January 2018

Long-term efficacy of imatinib in a practical setting is correlated with imatinib trough concentration that is influenced by body size: a report by the Nagasaki CML Study Group

1 reference

https://api.crossref.org/works/10.1111/J.1349-7006.2012.02253.X

21 January 2018

Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1111/J.1349-7006.2012.02253.X

21 January 2018

Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1111/J.1349-7006.2012.02253.X

21 January 2018

Standardization and quality control studies of 'real-time' quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia - a Europe Against Cancer program.

1 reference

https://api.crossref.org/works/10.1111/J.1349-7006.2012.02253.X

21 January 2018

Transcription-mediated amplification and hybridisation protection assay to determine BCR-ABL transcript levels in patients with chronic myeloid leukaemia

1 reference

https://api.crossref.org/works/10.1111/J.1349-7006.2012.02253.X

21 January 2018

High-throughput quantification of the anti-leukemia drug STI571 (Gleevec) and its main metabolite (CGP 74588) in human plasma using liquid chromatography-tandem mass spectrometry

1 reference

https://api.crossref.org/works/10.1111/J.1349-7006.2012.02253.X

21 January 2018

Imatinib mesylate (STI571) for treatment of children with Philadelphia chromosome-positive leukemia: results from a Children's Oncology Group phase 1 study

1 reference

https://api.crossref.org/works/10.1111/J.1349-7006.2012.02253.X

21 January 2018

Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet

1 reference

https://api.crossref.org/works/10.1111/J.1349-7006.2012.02253.X

21 January 2018

Multicenter prospective trial evaluating the tolerability of imatinib for Japanese patients with chronic myelogenous leukemia in the chronic phase: does body weight matter?

1 reference

https://api.crossref.org/works/10.1111/J.1349-7006.2012.02253.X

21 January 2018

Imatinib for newly diagnosed chronic-phase chronic myeloid leukemia: results of a prospective study in Japan

1 reference

https://api.crossref.org/works/10.1111/J.1349-7006.2012.02253.X

21 January 2018

Impact of early dose intensity on cytogenetic and molecular responses in chronic- phase CML patients receiving 600 mg/day of imatinib as initial therapy

1 reference

https://api.crossref.org/works/10.1111/J.1349-7006.2012.02253.X

21 January 2018

Phase III, randomized, open-label study of daily imatinib mesylate 400 mg versus 800 mg in patients with newly diagnosed, previously untreated chronic myeloid leukemia in chronic phase using molecular end points: tyrosine kinase inhibitor optimizati

1 reference

https://api.crossref.org/works/10.1111/J.1349-7006.2012.02253.X

21 January 2018

Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study

1 reference

https://api.crossref.org/works/10.1111/J.1349-7006.2012.02253.X

21 January 2018

Influence of CYP3A5 and drug transporter polymorphisms on imatinib trough concentration and clinical response among patients with chronic phase chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1111/J.1349-7006.2012.02253.X

21 January 2018

Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib.

1 reference

https://api.crossref.org/works/10.1111/J.1349-7006.2012.02253.X

21 January 2018

Prevalence, determinants, and outcomes of nonadherence to imatinib therapy in patients with chronic myeloid leukemia: the ADAGIO study.

1 reference

https://api.crossref.org/works/10.1111/J.1349-7006.2012.02253.X

21 January 2018

Survival benefit with imatinib mesylate versus interferon-alpha-based regimens in newly diagnosed chronic-phase chronic myelogenous leukemia

1 reference

https://pubmed.ncbi.nlm.nih.gov/22364419

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Association between imatinib transporters and metabolizing enzymes genotype and response in newly diagnosed chronic myeloid leukemia patients receiving imatinib therapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/22364419

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effects of the mean daily doses of imatinib during the first year on survival of patients with chronic myeloid leukemia in Japan: a study of the Hokkaido Hematology Study Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/22364419

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

[Correlation of quantification of major bcr-abl mRNA between TMA (transcription mediated amplification) method and real-time quantitative PCR].

1 reference

https://pubmed.ncbi.nlm.nih.gov/22364419

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia

1 reference

https://pubmed.ncbi.nlm.nih.gov/22364419

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Durable responses in chronic myeloid leukemia patients maintained with lower doses of imatinib mesylate after achieving molecular remission

1 reference

https://pubmed.ncbi.nlm.nih.gov/22364419

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Prognostic discrimination in "good-risk" chronic granulocytic leukemia.

1 reference

https://pubmed.ncbi.nlm.nih.gov/22364419

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

International Randomized Study of Interferon Vs STI571 (IRIS) 8-Year Follow up: Sustained Survival and Low Risk for Progression or Events in Patients with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Treated with Imatinib.

3

1 reference

10.1111/J.1349-7006.2012.02253.X

https://api.crossref.org/works/10.1111/J.1349-7006.2012.02253.X

25 December 2024

Identifiers

10.1111/J.1349-7006.2012.02253.X

1 reference

Europe PubMed Central

PubMed publication ID

30 May 2018

http://europepmc.org/abstract/MED/22364419

PMC publication ID

1 reference

National Center for Biotechnology Information

PubMed publication ID

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=22364419

25 December 2024

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

30 May 2018

http://europepmc.org/abstract/MED/22364419

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q54527295&oldid=2291330651"